BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33495197)

  • 1. TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
    Torres-Ayuso P; An E; Nyswaner KM; Bensen RC; Ritt DA; Specht SI; Das S; Andresson T; Cachau RE; Liang RJ; Ries AL; Robinson CM; Difilippantonio S; Gouker B; Bassel L; Karim BO; Miller CJ; Turk BE; Morrison DK; Brognard J
    Cancer Discov; 2021 Jun; 11(6):1411-1423. PubMed ID: 33495197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel aminothiazole KY-05009 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells.
    Kim J; Moon SH; Kim BT; Chae CH; Lee JY; Kim SH
    PLoS One; 2014; 9(10):e110180. PubMed ID: 25337707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.
    Nguyen T; Carrieri FA; Connis N; Lafargue A; Chang J; Chan A; Shetty AC; Song Y; Hoang T; Jagtap S; Chowdhury DD; Khan MA; Gabrielson KL; Rezaee M; Torres-Ayuso P; Brognard J; Hann CL; Tran PT
    Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38670554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
    Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
    Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
    Bensen R; Brognard J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
    Zhou W; Gao Y; Tong Y; Wu Q; Zhou Y; Li Y
    Pharmacol Res; 2021 Feb; 164():105392. PubMed ID: 33348023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.
    Zhang X; Kong M; Zhang Z; Xu S; Yan F; Wei L; Zhou J
    Thorac Cancer; 2017 Nov; 8(6):655-665. PubMed ID: 28906590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct conversion of osteosarcoma to adipocytes by targeting TNIK.
    Hirozane T; Masuda M; Sugano T; Sekita T; Goto N; Aoyama T; Sakagami T; Uno Y; Moriyama H; Sawa M; Asano N; Nakamura M; Matsumoto M; Nakayama R; Kondo T; Kawai A; Kobayashi E; Yamada T
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33400690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
    Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
    Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma.
    Li JZ; Gao W; Lei WB; Zhao J; Chan JY; Wei WI; Ho WK; Wong TS
    Oncotarget; 2016 Sep; 7(36):58218-58233. PubMed ID: 27533461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNIK inhibition abrogates colorectal cancer stemness.
    Masuda M; Uno Y; Ohbayashi N; Ohata H; Mimata A; Kukimoto-Niino M; Moriyama H; Kashimoto S; Inoue T; Goto N; Okamoto K; Shirouzu M; Sawa M; Yamada T
    Nat Commun; 2016 Aug; 7():12586. PubMed ID: 27562646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
    Lazzari C; Karachaliou N; Gregorc V; Bulotta A; Gonzalez-Cao M; Verlicchi A; Altavilla G; Rosell R; Santarpia M
    Expert Rev Respir Med; 2017 Jun; 11(6):469-479. PubMed ID: 28467720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
    Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT).
    Sun Y; Gao X; Wu P; Wink M; Li J; Dian L; Liang Z
    Phytomedicine; 2019 Oct; 63():153015. PubMed ID: 31302315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 3,4-Dihydrobenzo[
    Li Y; Zhang L; Yang R; Qiao Z; Wu M; Huang C; Tian C; Luo X; Yang W; Zhang Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):1786-1807. PubMed ID: 34985886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
    Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
    Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
    Bilguun EO; Kaira K; Kawabata-Iwakawa R; Rokudai S; Shimizu K; Yokobori T; Oyama T; Shirabe K; Nishiyama M
    BMC Cancer; 2020 Sep; 20(1):935. PubMed ID: 32993587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    Mäkinen N; Meyerson M
    J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37909331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.